

January 17, 2023

The National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
**(SYMBOL: THYROCARE)**

The Bombay Stock Exchange Ltd  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400 001  
**(SCRIP CODE 539871)**

Dear Sir/Madam,

**Sub: Prior Intimation under Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

--0--

Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, as amended, we wish to intimate that a meeting of the Board of Directors of the Company will be held on Friday, February 03, 2023, *inter alia*, to consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the Quarter / Nine Months ended December 31, 2022, and to consider and decide on payment of Interim Dividend, if any, for the financial year 2022-23.

We would also like to inform you that the trading window, which has been closed on January 01, 2023 for dealing in Company's equity shares by the Designated persons and their immediate relatives, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's internal code for prevention of Insider Trading, will reopen 48 hours after declaration of the unaudited results for the quarter ended December 31, 2022.

Kindly take the above intimations on your record.

Yours Faithfully,

For **Thyrocare Technologies Limited**,**Ramjee Dorai****Company Secretary and Compliance Officer**